Physician profile
Randall Barnes
NPI 1265461792
$6,791.79
in general payments reported to CMS, 2019-2025
47 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $602 · 2021: $1,179 · 2022: $967 · 2023: $1,140 · 2024: $784 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,873 · Education: $64.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,873.24 |
| Education | $64.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $633.34 | 2019-2025 | Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $607.32 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $471.12 | 2019-2022 | |
| Lilly USA, LLC | $429.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $402.64 | 2019-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $348.98 | 2019-2023 | Belsomra, Dificid, Steglatro |
| Astellas Pharma US INC | $332.99 | 2019-2022 | |
| Pfizer INC. | $325.67 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $275.36 | 2019-2023 | |
| Glaxosmithkline, LLC. | $265.64 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $250.41 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $246.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $189.25 | 2020-2025 | Nexletol |
| Dexcom, INC. | $165.51 | 2023-2025 | Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $151.34 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.